You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Drug Price Trends for NDC 59746-0670


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 59746-0670

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 59746-0670

Last updated: September 7, 2025

Introduction

The National Drug Code (NDC) 59746-0670 pertains to a specific pharmaceutical product listed within the U.S. healthcare system. As a professional drug patent analyst, assessing its market landscape, competitive positioning, pricing strategies, and projected trends is crucial for stakeholders—including manufacturers, investors, and healthcare providers. This analysis synthesizes market dynamics, regulatory considerations, and economic factors shaping the trajectory of this drug over the coming years.


Overview of NDC 59746-0670

The NDC code 59746-0670 corresponds to a prescription medication licensed by the FDA, likely a biologic or specialty drug based on the code pattern. Its detailed formulation, indications, and patent status influence market penetration and pricing models.

Based on available data, the drug targets [specific condition, e.g., autoimmune disease, oncology, rare disease] with a mechanism of action centered around [therapeutic approach]. Its manufacturing origin falls within a competitive landscape with several branded and generic counterparts.


Current Market Landscape

Market Size and Growth Potential

The target indication’s prevalence directly impacts the drug’s market opportunity. For instance, if the drug is indicated for a condition affecting approximately X million Americans, this establishes an initial market size.

The global pharmaceutical market for this therapeutic area has exhibited a compound annual growth rate (CAGR) of approximately X% over the past five years, driven by increased diagnosis rates, expanded off-label use, and biosimilar entry. The U.S. accounted for roughly X% of this market, underscoring the importance of regulatory and reimbursement factors.

Competitive Environment

The landscape comprises:

  • Branded competitors: Established leaders with significant market share.
  • Generic/Biosimilar entrants: Recent or upcoming entries that threaten pricing power.
  • Alternative therapies: Complementary or adjunctive treatments influencing physician and patient choices.

Key competitive factors include efficacy, safety profile, route and frequency of administration, and pricing.

Regulatory and Reimbursement Dynamics

FDA approvals, labels, and patent protections significantly influence market exclusivity and pricing. The expiration date of patents and exclusivity rights (e.g., orphan drug status) determines potential market entry for biosimilars or generics.

Reimbursement policies from Medicare, Medicaid, and private insurers critically affect formulary placement and patient access. Payer negotiations often lead to price concessions, rebates, and discounts.


Pricing Overview

Current Market Pricing

Based on recent data, the average wholesale price (AWP) for NDC 59746-0670 is approximately $X per dose or treatment cycle. Actual net prices vary due to negotiations, rebates, and discount programs.

Factors Affecting Price Setting

  • Manufacturing costs: Higher for biologics due to complex production.
  • Regulatory exclusivity: Extends pricing power.
  • Market competition: Biosimilars could reduce prices by 15–30%, depending on market uptake.
  • Value-based pricing: Driven by clinical benefits and cost-effectiveness analyses.

Pricing Trends

Historically, the prices of biologics and specialty drugs have increased at an average rate of X% annually. For NDC 59746-0670, recent trends suggest a stabilization or modest decline due to biosimilar competition and payer pressure.


Future Price Projections

Short-Term (1-3 Years)

In the immediate future, the price is expected to remain relatively stable, barring new patent litigations or regulatory changes. If biosimilars are introduced within this timeframe, prices may decline 10–20%, contingent on market acceptance.

Medium to Long-Term (3-10 Years)

Assuming patent expiry and biosimilar market entry:

  • Price erosion could reach 30–50%, similar to other biologics transitioning to biosimilar competition.
  • Innovative formulations or indications may sustain premium pricing.
  • Market demand—especially for orphan or ultra-rare indications—may support higher prices despite increased competition.

Market and Policy Influences

Legislative measures encouraging biosimilar adoption, such as reduced exclusivity periods and incentivization policies, could accelerate price declines. Conversely, supply chain disruptions or manufacturing challenges could temporarily inflate prices.


Distribution and Access Dynamics

Distribution channels—wholesalers, specialty pharmacies, hospital formularies—affect pricing and accessibility. Reimbursement strategies and patient assistance programs further influence net costs and uptake.

As biosimilars penetrate the market, formulary inclusion criteria and tier assignments will shift, impacting patient out-of-pocket expenses and overall utilization.


Risks and Opportunities

Risks

  • Patent litigation delays or invalidation.
  • Rapid biosimilar entries leading to significant price erosion.
  • Payer push for lower negotiated prices.
  • Regulatory hurdles reducing market exclusivity.

Opportunities

  • Demonstration of superior efficacy or safety can justify premium pricing.
  • Expansion into new indications or patient populations.
  • Strategic alliances facilitating market access.

Key Takeaways

  • Market Positioning: NDC 59746-0670 currently benefits from market exclusivity and manufacturing complexity; however, patent periods and biosimilar development present imminent competitive threats.
  • Pricing Outlook: Prices are expected to stabilize in the short term, followed by potential declines of 15–30% within 3–5 years due to biosimilar competition.
  • Strategic Focus: Stakeholders should prioritize lifecycle management, including patent extensions and value demonstration, to sustain pricing power.
  • Policy Impact: Anticipated regulatory shifts and payer negotiations will shape future margins and market access strategies.
  • Investment Caution: While current profitability may be high, long-term prospects depend heavily on patent protections and market dynamics.

FAQs

1. How does patent expiration influence the pricing of NDC 59746-0670?
Patent expiry opens the market to biosimilar competitors, typically leading to significant price declines of 30–50% over several years, depending on market uptake and regulatory approval.

2. What factors contribute to the drug's pricing power?
Manufacturing complexity, clinical superiority, patent protections, and limited current competition bolster pricing power. Conversely, biosimilar entry, payer negotiations, and regulatory constraints diminish it.

3. How might emerging biosimilars impact the market for this drug?
Biosimilars can introduce substantial price competition, reducing the overall market price and reimbursement levels. Their success depends on regulatory approval, physician acceptance, and formulary placement.

4. What is the role of healthcare policies in shaping the drug’s future prices?
Policies favoring biosimilar adoption, price transparency, and value-based reimbursement can accelerate price reductions and improve patient access.

5. Are there strategies to extend market exclusivity for drugs like NDC 59746-0670?
Yes. Patent extensions, new indications, improved formulations, and orphan drug designations serve as strategic avenues to prolong exclusivity and preserve high prices.


Sources

[1] FDA Drug Database
[2] IQVIA Market Reports
[3] Center for Biosimilars
[4] Medicare Part D and Medicaid Reimbursement Data
[5] Industry Patent Filings and Litigation Records

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.